20-22 August 2018

San Francisco, CA

Register by Friday, June 15 to Save $400

Workshop A
Monday, August 20 2018

09.00 - 12.00
Adding Radiology to the Pulmonary Fibrosis Equation
Workshop Leader: Mary Salvatore, Associate Professor of Radiology, Mount Sinai Medical Center

Advancements in the application of imaging techniques such as quantitative HRCT to inform and enrich clinical trials decisions undoubtedly goes hand-in-hand with the next generation of IPF drug development. Leveraging imaging’s capacity to advance biomarker identification, endpoint design and patient identification is now pivotal in advancing clinical translation and drug trial success.

Join your peers to discuss and evaluate:

  • Implementing HRCT as a means of early diagnosis of lung fibrosis for better insight into patient outcomes
  •  Utilizing HRCT for the correct diagnosis of IPF lung fibrosis against other ILD fibrosis to more confidently achieve correct diagnosis and better inform further clinical decisions
  • Demonstrating the use of HRCT as a surrogate biomarker of lung fibrosis to evaluate treatment response during drug development

Mary Salvatore, Associate Professor of Radiology, Mount Sinai Medical Center

Workshop B
Monday, August 20 2018

13.00 - 16.00
Using Genetic Information to Personalize Therapeutic Approaches for IPF
Workshop Leader: Timothy Blackwell, Professor of Cell & Developmental Biology, Vanderbilt University Medical Center Workshop Leader: Jonathan Kropski, Assistant Professor of Medicine, Vanderbilt University Medical Center

Poor prognosis, varying and unpredictable rates of progression despite treatment, and increasing population size means that the need for truly disease modifying IPF candidates is increasing. Is the answer precision therapy?

Harnessing an improved understanding of the genetic mechanisms driving IPF pathologies could offer insights into next generation, better clinical outcomes.

Be part of the discussion at this workshop on:

  • Using the at-risk phenotype to identify the early IPF phenotype
  • Evaluating rare genetic variants associated with IPF in both familial and sporadic cases, including telomerase and surfactant protein pathway mutations
  • Comparing rare variants with common variants as drivers within the IPF population, utility of next generation sequencing

Timothy Blackwell, Professor of Cell & Developmental Biology, Vanderbilt University Medical Center

Jonathan Kropski, Assistant Professor of Medicine, Vanderbilt University Medical Center